Literature DB >> 1525707

Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.

J Y Reginster1, M Azria, S Gaspar, M Bleicher, N Franchimont, M Behhar, A Albert, P Franchimont.   

Abstract

In order to evaluate the potential inhibition of the acute anti-osteoclastic activity of salmon calcitonin (SCT) by specific antibodies (Ab), we compared the SCT-induced hypocalcemic effect in young male rabbits with significant titers of high affinity Ab and in matched animals without Ab. Immunization of rabbits was performed by repetitive s.c. injections of SCT and Freund adjuvant. Ab were present in four-fifths of SCT-treated rabbits (Ab+). Their titer varied from 0.8 x 10(-9) to 30 x 10(-9) M/liter and their constant of affinity from 0.97 x 10(9) to 4.2 x 10(9) L/M. Intravenous injection of 1 IU/kg SCT to Ab+ rabbits induced a significant decrease (P less than 0.01) of ionized serum calcium (Ca2+) after 30 minutes (mean +/- SD: -9 +/- 0.6%) and until the 240th minute of the test (-16.7 +/- 4.7%), with a maximum after 120 minutes (-22.6 +/- 2%). This was not significantly different from the hypocalcemic effect measured after the same procedure performed in matched animals without Ab (Ab-): significant decrease in Ca2+ (P less than 0.01) after 30 minutes (-8.2 +/- 2.2%), maximal after 150 minutes (-23.2 +/- 4.9%), and lasting until 210 minutes (-14.5 +/- 3.7%). We conclude that, in the particular model of the male young rabbit, specific anti-SCT Ab do not block or reduce the acute anti-osteoclastic activity of SCT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525707     DOI: 10.1007/bf00582165

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  29 in total

1.  Quantitative aspects of the reaction between insulin and insulin-binding antibody.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

2.  Nasal calcitonin for treatment of established osteoporosis.

Authors:  K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

3.  Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.

Authors:  R Muff; M A Dambacher; J A Fischer
Journal:  Osteoporos Int       Date:  1991-02       Impact factor: 4.507

4.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

5.  Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia.

Authors:  O L Bijvoet; J van der Sluys Veer; A P Jansen
Journal:  Lancet       Date:  1968-04-27       Impact factor: 79.321

6.  Amino acid sequence of salmon ultimobranchial calcitonin.

Authors:  H D Niall; H T Keutmann; D H Copp; J T Potts
Journal:  Proc Natl Acad Sci U S A       Date:  1969-10       Impact factor: 11.205

7.  An evaluation of antibodies and clinical resistance to salmon calcitonin.

Authors:  F R Singer; J P Aldred; R M Neer; S M Krane; J T Potts; K J Bloch
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

8.  Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease.

Authors:  F Levy; R Muff; S Dotti-Sigrist; M A Dambacher; J A Fischer
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

Review 9.  Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.

Authors:  F R Singer; R S Fredericks; C Minkin
Journal:  Arthritis Rheum       Date:  1980-10

10.  Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects.

Authors:  S A BERSON; R S YALOW; A BAUMAN; M A ROTHSCHILD; K NEWERLY
Journal:  J Clin Invest       Date:  1956-02       Impact factor: 14.808

View more
  2 in total

1.  Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.

Authors:  N G Schipper; S G Romeijn; J Verhoef; F W Merkus
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

2.  Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.

Authors:  J Y Reginster; S Gaspar; R Deroisy; B Zegels; P Franchimont
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.